Flagship Pioneering’s newest startup is Expedition Medicines, a company whose artificial intelligence-driven technology platform analyzes the human proteome to learn the chemistry of binding small molecules to protein targets long considered “undruggable.” Expedition already has a cancer drug R&D alliance with Pfizer.
Eschewing the traditional model of financing biotech startups milestone to milestone to support a lead asset, Treeline Biosciences’ well-funded pipeline is comprised of multiple complementary programs. Select investors have supported the approach of Treeline, which said it has raised more than $1.1 billion to date.
Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.
AstraZeneca’s R&D collaboration with CSPC Pharmaceutical Group includes an oral small molecule for immunological diseases, which would offer a dosing edge over currently available injectable medications. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder.
Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never became a big part of the genetic testing company’s business, but it is getting a new life by joining Regeneron Genetics Center, a Regeneron subsidiary that analyzes genetic data for drug R&D.
Isomorphic Labs’ financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say.
Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech's Series B round will finance clinical tests of two programs, each addressing a different stage of the disease.
Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.
Thermo Fisher Scientific agreed to acquire the Purification and Filtration business of 3M spinoff Solventum. Filters and membranes from this business segment are used globally in applications such as biopharmaceutical manufacturing.
Improving the identification and validation of disease-specific drug targets in a cell-type and patient-specific manner early on will not only reduce the failure rate and cost that is so inherent in current drug development processes but also allow the development of more effective precision medicines, improving patient outcomes.
Memorial Sloan Kettering Cancer Center partnered with AWS to accelerate its research with AI. The collaboration seeks to speed up drug discovery and increase activity within the health system’s startup accelerator.
Merck’s implementation of artificial intelligence in drug research includes analyzing years of existing Merck clinical data to help identify which drugs and drug combinations to pursue. But Merck executive Matt Studney said AI is a tool to help, not replace humans.
Choosing the right brain injury rehabilitation program is a critical decision that can shape the future for you or your loved one.
Applications of SandboxAQ’s large quantitative models (LQMs) technology include running simulations that identify new biomarkers and optimize clinical development of drug candidates. The company spun out of Alphabet in 2022.
BenevolentAI said it will still develop its internally discovered drugs, but will now seek partners for them earlier in their development. Going forward, BenevolentAI will focus on making its AI technologies available to support the drug R&D efforts of its partners.
Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.
Halozyme’s offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring.
Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. During the recent MedCity News INVEST Digital Health conference, a panel discussed these applications and more.